Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey

Background Hereditary angioedema with C1 inhibitor deficiency (C1‐INH‐HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5–11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in eld...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and translational allergy 2019-07, Vol.9 (1), p.37-n/a, Article 37
Hauptverfasser: Bygum, Anette, Caballero, Teresa, Grumach, Anete S., Longhurst, Hilary J., Bouillet, Laurence, Aberer, Werner, Zanichelli, Andrea, Botha, Jaco, Andresen, Irmgard, Maurer, Marcus, Aberer, W., Grumach, A. S., Hakl, R., Bygum, A., Blanchard Delaunay, C., Boccon‐Gibod, I., Bouillet, L., Coppere, B., Du Thanh, A., Dzviga, C., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P. Y., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Sobel, A., Aygören‐Pürsün, E., Baş, M., Bauer, M., Bork, K., Greve, J., Magerl, M., Martinez‐Saguer, I., Maurer, M., Strassen, U., Papadopoulou‐Alataki, E., Psarros, F., Graif, Y., Kivity, S., Reshef, A., Toubi, E., Arcoleo, F., Bova, M., Cicardi, M., Manconi, P., Marone, G., Montinaro, V., Triggiani, M., Zanichelli, A., Baeza, M. L., Caballero, T., Cabañas, R., Guilarte, M., Hernandez, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marqués, L., Saenz de San Pedro, B., Björkander, J., Bethune, C., Garcez, T., Longhurst, H. J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Hereditary angioedema with C1 inhibitor deficiency (C1‐INH‐HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5–11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. Methods The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of icatibant. We conducted descriptive analyses in younger (age 
ISSN:2045-7022
2045-7022
DOI:10.1186/s13601-019-0272-9